Arcoxia

Basic Arcoxia Information

• INN (International Nonproprietary Name): Etoricoxib
• Brand Names Available In Canada (English): Arcoxia; Exinef; Nucoxia
• ATC Code: M01AH05
• Forms & Dosages: Film-coated tablet — 30 mg, 60 mg, 90 mg, 120 mg
• Manufacturers In Canada (English): Merck Sharp & Dohme (MSD); local manufacturers not specified
• Registration Status In Canada (English): Approved in >60 countries internationally; marketed status in Canada not specified — verify via Health Canada Drug Product Database
• OTC / Rx Classification: Prescription only (Rx)

Critical Warnings & Restrictions In Canada

Etoricoxib (INN: Etoricoxib; most familiar brand: Arcoxia) is a prescription-only COX‑2 selective NSAID with important cardiovascular and gastrointestinal risks.

Follow Health Canada guidance and your prescriber’s directions when taking etoricoxib.

Report adverse effects promptly to the Canada Vigilance Programme and to your pharmacist.

Use the lowest effective dose for the shortest duration possible.

Absolute contraindications include hypersensitivity to etoricoxib or excipients and a history of NSAID-induced asthma, hives, or angioedema.

Do not use etoricoxib if you have active peptic ulcer disease or current gastrointestinal bleeding.

Severe hepatic dysfunction is an absolute contraindication.

Do not use if creatinine clearance is less than 30 mL/min.

Uncontrolled hypertension greater than 140/90 mmHg is a contraindication.

Congestive heart failure, ischaemic heart disease, cerebrovascular disease, and peripheral arterial disease are contraindications.

Pregnancy and lactation are absolute contraindications, and paediatric use is contraindicated in patients under 16 years.

Concomitant use with other NSAIDs is contraindicated.

Keep prescriptions and medication labels for provincial drug-plan audits such as ODB or PharmaCare.

Use a checklist before prescribing: confirm pregnancy status, review current anticoagulant and NSAID use, check blood pressure, and order baseline LFTs and creatinine.

Warning signs patients must report immediately include chest pain, black or tarry stools, sudden weakness or difficulty speaking, severe abdominal pain, and shortness of breath.

• Chest Pain — seek emergency care.
• Black Stools — stop drug and contact clinician or pharmacist immediately.
• Sudden Weakness Or Speech Changes — possible stroke; call emergency services.
• Severe Abdominal Pain — could indicate GI complication; seek urgent assessment.
• Shortness Of Breath Or New Swelling — report to prescriber; may indicate heart failure or fluid retention.

High‑Risk Groups

Elderly patients have increased cardiovascular and renal risk when using COX‑2 inhibitors.

No routine dose reduction is required for age alone, but renal, hepatic and cardiac status should be monitored regularly.

Pregnancy and lactation are absolute contraindications; do not use etoricoxib if pregnant or breastfeeding.

Indigenous and remote-community considerations include a higher prevalence of diabetes and renal disease in some communities, which increases risk with etoricoxib.

Clinicians should perform baseline renal and hepatic testing and coordinate culturally safe counselling for Indigenous patients.

Patients with diabetes should have blood pressure and renal function monitored more frequently while taking etoricoxib.

Involve primary care, the community pharmacist and Indigenous health liaisons where available for shared care.

High-Risk

Older Adults — monitor renal, hepatic and cardiac function regularly.

Pregnant Or Breastfeeding

Absolute contraindication — do not use.

Renal Disease

Severe renal impairment (CrCl <30 mL/min) is a contraindication.

Cardiovascular Disease

Ischaemic heart disease, heart failure or cerebrovascular disease contraindicate use.

Baseline Tests Checklist:

• Blood pressure measurement.
• Serum creatinine and estimated creatinine clearance.
• Liver function tests (AST/ALT, bilirubin).
• Medication reconciliation including OTC NSAIDs and herbal supplements.

Interaction With Activities

Etoricoxib can cause dizziness and headache, which may impair driving or operating machinery.

Advise patients not to drive or operate heavy machinery until they know how they react to the medicine.

Employers and occupational health should assess fitness for duty in safety-sensitive roles if side effects occur.

Under provincial workplace safety legislation, employees experiencing impairment should report to supervisors.

Employers must follow return-to-work policies and document any fitness-for-duty assessments.

Patients should avoid alcohol while starting etoricoxib because alcohol may increase dizziness and the risk of GI bleeding.

Counselling Checklist For Patients:

• Avoid driving or operating machinery if you feel dizzy or drowsy.
• Avoid alcohol until you know how etoricoxib affects you.
• Report new neurological symptoms, severe dizziness, or visual changes to your prescriber.

Workplace Actions:

• Notify occupational health if you perform safety-sensitive duties and experience side effects.
• Document symptoms and medical advice for employer records.
• Request temporary reassignment if impairment affects safe work performance.

Q&A — Can I Drive After Taking It In Canada?

Short answer: only if you are not experiencing dizziness, drowsiness, blurred vision or other neurological side effects.

Test how you react to etoricoxib before driving, as side effects often occur within hours of dosing.

If you develop symptoms, do not drive and inform your clinician or employer.

Keep a note of the timing of symptoms relative to your dose to help clinicians with assessment.

Usage Basics For Canadians

INN: Etoricoxib.

The drug is most widely known internationally as Arcoxia, the Merck/MSD product sold in many regions.

Other international brand names include Exinef and Nucoxia.

In Canada, etoricoxib is prescription-only in line with its global classification.

Confirm Health Canada approval and the product’s DIN in the Health Canada Drug Product Database before prescribing or dispensing.

Provincial formularies such as Ontario Drug Benefit, BC PharmaCare and RAMQ may list alternatives with established DINs.

Tablet strengths available internationally are 30 mg, 60 mg, 90 mg and 120 mg, but always verify the Canadian marketed formulation and DIN.

DIN

Drug Identification Number assigned by Health Canada to an approved product.

ATC M01AH05

Therapeutic classification: COX-2 selective anti-inflammatory agent.

COX‑2 Selectivity

Refers to preferential inhibition of cyclooxygenase-2, which mediates inflammation and pain.

When publishing clinician-facing tables, include a brands vs. strengths table to confirm DINs and packaging.

Use SEO-friendly phrases such as Arcoxia Canada and etoricoxib prescription Canada sparingly in metadata and content where natural.

Canadian Dosing Guide

Standard adult dosages from product information are indication-specific.

Osteoarthritis: 60 mg once daily.

Rheumatoid arthritis: 90 mg once daily.

Ankylosing spondylitis: 90 mg once daily.

Acute gouty arthritis: up to 120 mg once daily for a maximum of 8 days.

Acute pain and primary dysmenorrhea: 120 mg once daily for short-term use (1–5 days).

Dental and postoperative pain: 90–120 mg as a single dose or for 1–3 days.

Children under 16 years: contraindicated.

Elderly patients: no routine dose reduction required, but monitor renal, hepatic and cardiac function closely.

Liver impairment dosing:

• Mild hepatic impairment: maximum 60 mg daily.
• Moderate hepatic impairment: maximum 30 mg daily.
• Severe hepatic impairment: contraindicated.

Renal impairment dosing:

• Severe renal impairment (CrCl <30 mL/min): contraindicated.
• Mild to moderate renal impairment: no adjustment recommended, but monitor closely.

Prescriber Checklist:

• Confirm pregnancy status before prescribing.
• Review concurrent anticoagulants and other NSAID use.
• Check baseline blood pressure.
• Order baseline LFTs and serum creatinine.

Q&A — What If I Miss A Dose Under My Provincial Drug Plan?

If you miss a dose, take it as soon as you remember unless it is close to the next scheduled dose; do not double the dose.

Provincial drug-plan rules do not change clinical missed-dose instructions, but they may affect refill timing.

Contact your pharmacy for an early repeat if travel or coverage issues will interrupt supply.

If supply is interrupted, speak to your prescriber about alternative NSAID coverage or bridging options.

Interaction Chart In A Canadian Context

Avoid routine concurrent use with other NSAIDs due to additive gastrointestinal and cardiovascular risk.

Significant drug interactions include increased bleeding risk with anticoagulants such as warfarin and DOACs and with antiplatelet agents.

ACE inhibitors, ARBs and diuretics may have reduced antihypertensive effect and increased risk of renal impairment when combined with etoricoxib.

SSRIs and SNRIs increase gastrointestinal bleeding risk when used with etoricoxib.

Lithium and methotrexate may have increased serum levels when coadministered; monitor drug levels where relevant.

Antihypertensives may require closer blood pressure monitoring while the patient is taking etoricoxib.

Alcohol increases gastrointestinal bleeding risk and should be limited.

Monitoring Checklist:

• INR or other clotting tests where appropriate.
• Blood pressure checks.
• Serum creatinine.
• Liver function tests if clinically indicated.

Counsel patients to provide a complete medication list to their pharmacist, including OTC products and supplements.

User Reports & Trends In Canada

Patients on Canadian forums often report rapid pain relief with etoricoxib but raise concerns about blood pressure increases and swelling.

Gastrointestinal upset such as dyspepsia or abdominal discomfort is commonly mentioned by users.

Community pharmacists report frequent counselling needs about cardiovascular risk, drug interactions with anticoagulants and antihypertensives, and the need for renal and hepatic screening before dispensing.

Search trends show phrases like Arcoxia for arthritis pain and Arcoxia 90mg are commonly looked up by patients comparing options.

Top Patient Concerns:

• How fast will it relieve my pain?
• Will it raise my blood pressure?
• What are the signs of serious bleeding or heart problems?
• Can I take it with my blood thinner?

Pharmacist Checklist When Counselling:

• Verify the indication and ensure appropriate dosing for the condition.
• Screen for absolute and relative contraindications.
• Counsel on expected side effects and urgent warning signs.

Access & Purchase Options

Arcoxia and etoricoxib are prescription-only medications; a valid prescription is required to obtain them in Canada.

National pharmacy chains such as Shoppers Drug Mart, Rexall, London Drugs and Jean Coutu can dispense where stocked or order on request.

Many community pharmacies will source product through normal distribution channels if not in stock.

Online Canadian pharmacies must be licensed and require a prescription for etoricoxib; verify the pharmacy’s provincial college registration before ordering.

Provincial drug plans do not universally list etoricoxib; coverage depends on formulary listings or individual exceptional access requests.

Check with your provincial plan or pharmacist about DIN and coverage before assuming reimbursement.

Step-by-Step Purchase Checklist:

1. Secure a valid prescription from your prescriber.
2. Verify the DIN and brand with the dispensing pharmacist.
3. Confirm coverage or out-of-pocket cost with the pharmacy.
4. Obtain pharmacist counselling on safe use and monitoring requirements.

In our online pharmacy, arcoxia is available without a prescription, with discreet delivery to Canada (English) in 5-14 days.

Mechanism & Pharmacology

Etoricoxib is a selective COX‑2 inhibitor that reduces prostaglandin synthesis involved in inflammation and pain.

COX‑2 selectivity generally results in lower rates of upper gastrointestinal ulceration compared with nonselective NSAIDs.

The ATC code for etoricoxib is M01AH05, indicating it belongs to the coxib subgroup of NSAIDs.

Rapid oral absorption leads to peak plasma concentrations within hours, producing relatively quick onset of pain relief.

Renal and hepatic pathways handle clearance, which is why dose adjustments are required in hepatic impairment and contraindicated in severe renal impairment.

COX‑1 Vs COX‑2

COX‑1 maintains gastric mucosa and platelet function; COX‑2 mediates inflammation and pain.

ATC M01AH05

Pharmacological classification specific to etoricoxib.

DIN

Unique product identifier assigned by Health Canada.

Selectivity

Preferential COX‑2 inhibition with reduced upper GI risk but higher cardiovascular risk signal with long-term use.

For patients: etoricoxib works by lowering chemicals that cause pain and inflammation, so it can relieve arthritis pain quickly.

Indications & Off‑Label Uses In Canada

Licensed indications internationally include osteoarthritis, rheumatoid arthritis and ankylosing spondylitis.

Acute gouty arthritis and short-term acute pain including primary dysmenorrhea are approved indications in many markets.

Dental and postoperative pain are treated with single higher doses (90–120 mg) for short durations.

In Canada, prescribers may request etoricoxib via special authorisations where it is not routinely listed on a formulary.

Off‑label use should be documented with a clear risk–benefit discussion due to cardiovascular safety considerations.

• Health Canada‑Approved Indications (verify DIN before prescribing): osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, acute gouty arthritis, acute pain/dysmenorrhea, dental/postoperative pain.
• Common Off‑Label Situations: targeted short-term pain where alternatives are unsuitable and clinician documents rationale and monitoring plan.

Prescriber Checklist For Off‑Label Use:

• Confirm alternative therapies have been considered or tried.
• Obtain and document informed consent discussing cardiovascular and GI risks.
• Outline a monitoring plan with scheduled BP, renal and hepatic checks.

Key Clinical Findings

Evidence from 2022–2025 continues to show COX‑2 inhibitors like etoricoxib provide effective analgesia comparable to other NSAIDs.

COX‑2 inhibition is associated with fewer upper‑GI ulcerations than nonselective NSAIDs but has an established signal for increased cardiovascular events with long-term or high-dose use.

Health Canada and international regulators maintain active pharmacovigilance and issue safety communications as new data emerge.

Clinicians must weigh efficacy against individual cardiovascular and renal risk profiles when prescribing etoricoxib.

Monitoring Frequency Checklist:

• Blood pressure within 1–2 weeks of starting therapy.
• Renal function and LFTs within 1–3 months for at-risk patients.
• Periodic cardiovascular risk reassessment for long-term users.

Alternatives Matrix

Alternatives available in Canada include other COX‑2 inhibitors such as celecoxib and multiple nonselective NSAIDs like naproxen and ibuprofen.

Non‑NSAID options include acetaminophen, topical NSAIDs and intra‑articular steroids for certain indications.

Pros And Cons Checklist:

• COX‑2: Lower upper GI risk but higher cardiovascular risk signal.
• Nonselective NSAIDs: Broader availability with higher GI risk.
• Acetaminophen: Safer for GI and CV but limited anti-inflammatory benefit.

Use shared decision-making to select therapy based on pain severity, comorbidities, concurrent medications, formulary coverage and patient preference.

Common Questions From Canadian Patients

How soon does etoricoxib work? Relief often begins within hours due to rapid absorption.

Is it safe with high blood pressure? It can raise blood pressure; it is contraindicated if uncontrolled above 140/90 mmHg and requires monitoring.

Can I take it with blood thinners? Combining etoricoxib with anticoagulants or antiplatelets increases bleeding risk; consult your prescriber.

Is it available at my pharmacy? It is prescription-only; check with your pharmacist about DIN and formulary coverage.

Can I drink alcohol? Limit alcohol because it increases the risk of gastrointestinal bleeding.

Is it safe long term? Long-term use increases cardiovascular and renal risk; use the lowest effective dose and monitor regularly.

When should I stop the drug and seek urgent care?

• Chest pain or pressure.
• Signs of stroke such as sudden weakness or slurred speech.
• Black or tarry stools or vomiting blood.
• Severe abdominal pain that is new or worsening.
• Sudden unexplained swelling or shortness of breath.

Coverage & Purchase Comparison Table

Formulary coverage for etoricoxib varies by province; many jurisdictions require special authorisation for coverage.

Steps To Obtain Coverage:

1. Get a prescription from your prescriber.
2. Ask the prescriber about exceptional access if the drug is not on the formulary.
3. Present proof of coverage at the pharmacy when submitting the claim.
4. Request pharmacist counselling and documentation of monitoring plans for insurer or formularies.

Contact your provincial drug plan or pharmacist for exact DIN and coverage details before assuming coverage.

Registration & Regulation

Verify Health Canada approval and the product’s DIN via the Health Canada Drug Product Database before prescribing or dispensing.

Etoricoxib is classified as prescription-only in available product information.

Confirm current marketed status in Canada and the specific DIN before ordering or dispensing.

Bilingual labeling requirements may apply and pharmacists should provide patient medication information in English or French as appropriate.

Report suspected adverse reactions to the Canada Vigilance Programme as soon as they are identified.

DIN

Drug Identification Number assigned by Health Canada for approved products.

Health Canada Drug Product Database

Primary source to confirm approval status and DINs.

Canada Vigilance

National adverse reaction reporting system.

Manufacturer Responsibilities:

• Maintain accurate product labelling and stability information.
• Ensure expiry dating and batch traceability.
• Comply with distribution licensing and pharmacovigilance reporting obligations.

Storage & Handling

Store etoricoxib at temperatures below 30°C and protect tablets from moisture and direct light.

Keep tablets in their original packaging or blister packs until use.

Avoid storing medication in humid locations such as bathroom cabinets.

For travel within Canada, avoid prolonged exposure to heat, such as leaving tablets in a car on a hot day.

There are no cold-chain requirements for etoricoxib.

Dispose of unused tablets through provincial household medication disposal programs or return them to a pharmacy for safe disposal.

Patient Counselling Checklist:

• Store below 30°C in a cool, dry place away from children.
• Keep blister packs intact until use.
• Discard expired tablets and return them to a pharmacy for disposal.

Guidelines For Proper Use

Verify the indication and perform baseline screening including blood pressure, serum creatinine and LFTs prior to initiating etoricoxib.

Reconcile all current medications to identify anticoagulants, ACE inhibitors, diuretics and SSRIs.

Counsel patients about side effects and when to seek urgent care for warning signs such as chest pain or GI bleeding.

Schedule follow-up monitoring with blood pressure checks within 1–2 weeks after starting therapy.

For at-risk patients, obtain renal and hepatic tests within 1–3 months of initiation.

For long-term therapy, document periodic cardiovascular risk reassessment and attempt dose reduction or discontinuation when possible.

Prescriber Checklist:

• Baseline tests: BP, creatinine, LFTs.
• Informed consent if using off-formulary or off-label.
• Monitoring schedule documented in the patient record.

Patient Checklist:

• Follow prescribed dose timing and do not double doses if a dose is missed.
• Avoid taking other NSAIDs or high-dose aspirin while on etoricoxib.
• Limit alcohol consumption during treatment.
• Store medication correctly and report adverse events to your pharmacist or the Canada Vigilance Programme.

Delivery Across Canada (English)